Opioid receptor antagonists in the treatment of pathological gambling

Maurizio Coppola, MD; Raffaella Mondola, MD

doi:10.5055/jom.2017.0388

Authors

Maurizio Coppola, MD
Raffaella Mondola, MD

DOI:

https://doi.org/10.5055/jom.2017.0388

Abstract

no abstract

Author Biographies

Maurizio Coppola, MD

Department of Addiction, ASL CN2, Alba, Italy

Raffaella Mondola, MD

Department of Mental Health, ASL CN1, Saluzzo, Italy

References

Fauth-Bühler M, Mann K, Potenza MN: Pathological gambling: A review of the neurobiological evidence relevant for its classification as an addictive disorder. Addict Biol. 2017; 22: 885-897.

Choi SW, Shin YC, Kim DJ, et al.: Treatment modalities for patients with gambling disorder. Ann Gen Psychiatry. 2017; 16: 23.

Kim SW, Grant JE, Adson DE, et al.: Double-blind naltrexone and placebo comparison study in the treatment of pathological gambling. Biol Psychiatry. 2001; 49: 914-921.

Dannon PN, Lowengrub K, Musin E, et al.: Sustained-release bupropion versus naltrexone in the treatment of pathological gambling: A preliminary blind-rater study. J Clin Psychopharmacol. 2005; 25: 593-596.

Dannon PN, Lowengrub K, Musin E, et al.: 12-month follow-up study of drug treatment in pathological gamblers: A primary out come study. J Clin Psychopharmacol. 2007; 27: 620-624.

Grant JE, Kim SW, Hartman BK.: A double-blind, placebo-controlled study of the opiate antagonist naltrexone in the treatment of pathological gambling. J Clin Psychiatry. 2008; 69: 783-789.

Lahti T, Halme JT, Pankakoski M et al.: Treatment of pathological gambling with naltrexone pharmacotherapy and brief intervention: a pilot study. Psychopharmacol Bull. 2010; 43: 35-44.

Bosco D, Plastino M, Colica C, et al.: Opioid antagonists naltrexone for the treatment of pathological gambling in Parkinson’s disease. Clin Neuropsychopharmacol. 2012; 35: 118-120.

Kovanen L, Basnet S, Castrén S, et al.: A randomised, double-blind, placebo-controlled trial of as-needed naltrexone in the treatment of pathological gambling. Eur Addict Res. 2016; 22: 70-79.

Grant JE, Potenza MN, Hollander E, et al.: Multicenter investigation of the opioid antagonist nalmefene in the treatment of pathological gambling. Am J Psychiatry. 2006; 163: 303-312.

Grant JE, Odlaug BL, Potenza MN, et al.: Nalmefene in the treatment of pathological gambling: multicentre, double-blind, placebo-controlled study. Br J Psychiatry. 2010; 197: 330-331.

Pecina S, Smith KS, Berridge KC.: Hedonic hot spots in the brain. Neuroscientist. 2006; 12: 500-511.

Barbano MF, Cador M.: Opioid for hedonic experience and dopamine to get ready for it. Psychopharmacology. 2007;191: 497-506.

Petrovic P, Pleger B, Seymour B, et al.: Blocking central opiate function modulates hedonic impact and anterior cingulated response to reward and losses. J Neurosci. 2008; 28: 10509-10516.

Porchet RI, Boekhoudt L, Studer B, et al.: Opioidergic and dopaminergic manipulation of gambling tendencies: a preliminary study in male recreational gamblers. Front Behav Neurosci. 2016; 7: 138.

Crowley TJ, Wagner JE, Zerbe G, et al.: Naltrexone-induced dysphoria in former opioid addicts. Am J Psychiatry. 1985; 142(9):1081–1084.

Verebey KG, Mulé SJ.: Naltrexone (Trexan): a review of hepatotoxicity issues. NIDA Res Monogr. 1986; 67: 73-81.